Mayne Pharma Group Limited (Mayne Pharma) is an ASX-listed specialty pharmaceutical company that develops and manufactures branded and generic products, which it distributes directly or through distribution partners and also provides contract development and manufacturing services.
Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems for both generic and proprietary applications including:
Lozanoc® – super-bioavailable itraconazole used to treat fungal infections.
Doryx® – delayed-release oral formulation of doxycycline used to treat acne, certain bacterial infections or as an anti-malarial
Astrix® – delayed-release low-dose aspirin used to treat cardiovascular disease
Eryc® – delayed-release erythromycin used in the tr...